|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Fungal Panel 3, Immunodiffusion
Test Code37699
Includes
Aspergillus Antibodies, Immunodiffusion
Blastomyces Antibody, Immunodiffusion
Candida Antibody, Immunodiffusion
Coccidioides Antibody (IgG), Immunodiffusion
Histoplasma Antibody, Immunodiffusion
Blastomyces Antibody, Immunodiffusion
Candida Antibody, Immunodiffusion
Coccidioides Antibody (IgG), Immunodiffusion
Histoplasma Antibody, Immunodiffusion
Preferred Specimen
2 mL serum
Minimum Volume
1 mL
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic • Grossly icteric
Methodology
Immunodiffusion (ID)
Setup Schedule
Set up: Mon, Wed, Fri, Sat; Report available: 3-6 days
Clinical Significance
This panel may be used as an aid in the diagnosis of several fungal infections that can cause serious infection. This qualitative immunodiffusion-based test is designed to detect serum antibodies directed against Aspergillus species (specifically A. flavus, A. fumigatus, A. niger), Blastomyces dermatitidis, Candida species, Coccidioides immitis, and Histoplasma capsulatum.
These fungi may cause invasive infections that can represent a diagnostic challenge. While the endemic mycoses may have differing epidemiological risk factors, clinically they may have overlapping features. Thus, definitive diagnosis depends on fungal culture, characteristic fungal staining in specimens, or other direct diagnostic means, such as molecular methods, that may require invasive procedures.
Immunodiffusion bands of identity or partial identity with a positive control are considered positive and indicate patient antibody against the fungal antigen in question. Negative results do not rule out infection, especially if testing is done before antibody development early in infection or if the patient is immunocompromised. Test results should be correlated with the patient's epidemiological risk factors and clinical findings.
These fungi may cause invasive infections that can represent a diagnostic challenge. While the endemic mycoses may have differing epidemiological risk factors, clinically they may have overlapping features. Thus, definitive diagnosis depends on fungal culture, characteristic fungal staining in specimens, or other direct diagnostic means, such as molecular methods, that may require invasive procedures.
Immunodiffusion bands of identity or partial identity with a positive control are considered positive and indicate patient antibody against the fungal antigen in question. Negative results do not rule out infection, especially if testing is done before antibody development early in infection or if the patient is immunocompromised. Test results should be correlated with the patient's epidemiological risk factors and clinical findings.
